Skip to main content
Alphanox Co.,Ltd. logo

Alphanox Co.,Ltd. — Investor Relations & Filings

Ticker · 043100 ISIN · KR7043100007 KO Manufacturing
Open in API
Filings indexed 364 across all filing types
Latest filing 2024-03-14 M&A Activity
Country KR South Korea
Listing KO 043100

About Alphanox Co.,Ltd.

https://alphanox.co.kr/en/

Alphanox Co.,Ltd., formerly known as Solco Biomedical, is a global medical and healthcare group established in 1974. The company specializes in the development, manufacturing, and sale of advanced medical devices and health-promoting products. Its primary product lines include surgical instruments, orthopedic implants with a strong focus on spinal applications, and in-vitro diagnostic devices. In addition to its core medical offerings, Alphanox also produces healthcare products such as functional water and other health-promoting devices. The company is committed to improving quality of life through extensive research and development grounded in medical engineering and clinical results.

Recent filings

Filing Released Lang Actions
[첨부추가]경영권변경등에관한계약체결
M&A Activity Classification · 100% confidence The document is a regulatory filing regarding a 'Change in Management Control' (경영권 변경 등에 관한 계약 체결) involving a share transfer and future board changes. This type of corporate event, involving a change in the controlling shareholder and associated contractual agreements, is classified under M&A Activity (TAR) as it pertains to the transfer of ownership and control of the company.
2024-03-14 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Solco Biomedical) announcing a significant change in financial results (revenue or profit/loss structure exceeding 30%). It provides a summary table of financial performance (revenue, operating profit, net income) and explains the reasons for the variance. This is a standard 'Earnings Release' (ER) type of disclosure in the Korean market, as it provides the initial announcement of financial results before the final audited annual report is published. FY 2023
2024-02-23 Korean
전환사채(해외전환사채포함)발행후만기전사채취득(제12회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing regarding the 'Acquisition of Convertible Bonds before Maturity' (전환사채 발행후 만기전 사채 취득). It details the specific terms of the bond, the acquisition amount, the reason (Put Option exercise), and the method of acquisition. This falls under capital structure and financing updates, specifically related to debt instruments, which is best classified as a Capital/Financing Update (CAP).
2024-01-29 Korean
자산재평가결과(자율공시)
Regulatory Filings Classification · 100% confidence The document is a formal disclosure regarding the results of an asset revaluation (자산재평가결과) for Solco Biomedical. It details the revaluation of land assets, the resulting financial impact on the balance sheet (increase in assets and equity), and the valuation firm used. Since this is a specific regulatory disclosure regarding financial position and asset valuation that does not fit into standard categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2023-12-27 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a formal notice regarding the setting of a record date for the purpose of holding an Annual General Meeting (AGM). It specifies the record date (2023-12-31) and the reason (holding the 29th Annual General Meeting). Since this is a regulatory announcement regarding the preparation for an AGM rather than the meeting materials themselves, and it does not fit into other specific categories like dividend or share issuance, it is classified as a general regulatory filing.
2023-12-15 Korean
자산재평가실시결정(자율공시)
Regulatory Filings Classification · 100% confidence The document is a formal announcement regarding a decision to perform an asset revaluation (자산재평가 실시 결정). It details the assets involved, the valuation date, the appraisal firm, and the purpose of the revaluation (financial structure improvement). Since this is a specific regulatory disclosure regarding corporate assets and financial reporting adjustments that does not fit into the other specific categories like earnings or dividends, it is classified as a general regulatory filing.
2023-12-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.